Esophageal CancerISCONNCT03896399
Laparoscopic Ischemic Conditioning Prior to Esophagectomy
A study testing Laparoscopic ischemic conditioning followed by esophagectomy in people with Esophageal Cancer, run by UMC Utrecht at 2 sites in 2 countries.
Trial summary
This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification scores on pre-op CT-scan. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Esophageal Cancer
- What is being tested?
- Laparoscopic ischemic conditioning followed by esophagectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 11 Nov 2019to 2 May 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically proven adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ)
- Planned to undergo transthoracic esophagectomy or transhiatal esophagectomy
- Preoperative computed tomography (CT)
- Vascular arterial changes: "major calcifications" of the thoracic aorta according to the "Uniform calcification score" (UCS) and or a stenosis of the celiac axis according to the "modified NASCET score". (Appendix 1 and 2) (7,17)
- ASA I-III
- European Clinical Oncology Group (ECOG) performance status of 0,1 or 2
- Age > 17
- Written informed consent
Who cannot join
- Not able to undergo study treatment.
- Metastatic disease (M1)
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Germany1 site
University Hospital of Cologne
Cologne, North Rhine-Westphalia, 50937
About this study
Official title: Laparoscopic Ischemic Conditioning Prior to Esophagectomy in Patients With Esophageal Cancer and Arterial Calcifications
This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification scores on pre-op CT-scan. In these patients, laparoscopic ischemic conditioning is performed 12-18 days before an Ivor-Lewis esophagectomy. The primary outcome is all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after the laparoscopic ischemic conditioning. Secondary outcomes are complications after the esophagectomy, and the induction of angiogenesis by biomarkers of microcirculation and redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography.
Read the detailed description
Rationale:
Anastomotic leakage is the most important surgical complication following esophagectomy for esophageal cancer, leading to increased morbidity and mortality. A major cause of leakage is impaired healing due to ischemia of the gastric tube that is used for reconstruction of the gastrointestinal tract. Calcifications of the aorta or stenosis of the celiac trunk on pre-operative CT scan have been shown to be associated with an increased risk of anastomotic leakage. So far, no individualized treatment has been initiated for this selected group of patients. Laparoscopic ischemic conditioning (ISCON) of the gastric tube aims to increase perfusion at the anastomotic site by redistribution of the gastric blood flow and/or induction of angiogenesis. This is achieved by occlusion of the supplying gastric arteries except for the right gastroepiploic artery during a separate intervention prior to esophagectomy. Of note, these arteries would also be occluded during conventional esophagectomy, but with laparoscopic ISCON they are occluded at an earlier moment in time during a separate intervention. Retrospective studies have demonstrated the safety of this technique. Prospective studies have not yet been performed.
Primary objective:
Assess the safety and feasibility of laparoscopic ISCON 12-18 days prior to esophagectomy for esophageal cancer in patients with arterial calcifications.
Study design:
Two center phase II prospective single-arm safety and feasibility trial.
Study population:
Patients with resectable esophageal carcinoma (cT1-4a, N0-3, M0) with "major calcifications" of the thoracic aorta (UCS) and any additional calcification or stenosis of the celiac axis (modified NASCET score) on preoperative CT scan, who are planned to undergo esophagectomy.
Intervention:
Laparoscopic ISCON followed by esophagectomy after an interval of 12-18 days.
Primary outcome:
all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after operation 1 (laparoscopic ISCON) and before operation 2 (esophagectomy).
Secondary outcomes:
secondary outcomes with regard to operation 1 (laparoscopic ISCON) are the duration of the procedure, blood loss, day of discharge postoperatively and grade 1 complications. Secondary outcomes with regard to operation 2 (esophagectomy) are anastomotic leakage rate, all other grade 3b or higher complications and 30 day mortality. Further secondary endpoints are the induction of angiogenesis by biomarkers of microcirculation and redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
the additional burden for the patient consists of an extra operation of approximately 40 minutes during which laparoscopic ISCON will be performed, prior to the planned esophagectomy. We would classify the current study as medium risk. Potential benefits in comparison to current standard treatment are a reduced risk of anastomotic leakage and severity of anastomotic leakage. Potential risks are complications following operation 1 (laparoscopic ISCON). Mainly, based upon prior experience, we expect gastroparesis to occur in 25% of patients. Patients with gastroparesis have an increased risk of aspiration and will require a stomach emptying by nasogastric tube and nasojejunal tube feeding till the performance of operating 2 (esophagectomy).
- Conditions
- Esophageal Cancer
- Being tested
- Laparoscopic ischemic conditioning followed by esophagectomy
- Keywords
- Esophageal Cancer, Esophagectomy, Ischemic conditioning
- Medical subject headings
- Esophageal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Laparoscopic ischemic conditioning followed by esophagectomyProcedure or surgery
All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
| Study group | Role | What they receive |
|---|---|---|
| Laparoscopic ischemic conditioning followed by esophagectomy | Experimental | All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days. Receives: Procedure: Laparoscopic ischemic conditioning followed by esophagectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning
Complications grade 2 and higher (Clavien-Dindo classification)
Measured: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.
Secondary outcomes (10)
Number of participants with a grade 1 complication after operation 1 (laparoscopic ISCON)
Grade 1 complications after operation 1 (laparoscopic ISCON)
Measured: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.
Duration of operation 1 (laparoscopic ISCON)
Duration of operation 1 (laparoscopic ISCON)
Measured: During operation 1
Bloodloss during operation 1 (laparoscopic ISCON)
Bloodloss during operation 1 (laparoscopic ISCON)
Measured: During operation 1
Day of discharge after operation 1 (laparoscopic ISCON)
Day of discharge after operation 1 (laparoscopic ISCON)
Measured: After operation 1, usually on the third post-operative day
Number of participants with anastomotic leakage after operation 2 (esophagectomy)
Anastomotic leakage after operation 2 (esophagectomy)
Measured: Within 30 days after operation 2
Number of participants with grade 3b or higher complications after operation 2 (esophagectomy)
Grade 3b (Clavien-Dindo classification) or higher complications after operation 2 (esophagectomy)
Measured: Within 30 days after operation 2
Number of participants with 30 day mortality after operation 2 (esophagectomy)
30 day mortality after operation 2 (esophagectomy)
Measured: Within 30 days after operation 2
Induction of angiogenesis in tissue
Paraffin embedded sections (10µm) will be stained by immunohistochemistry against CD31 (vessel density) or smooth-muscle-actin positive pericytes to characterize vascularity
Measured: Biopsies are taken at the start, or within 24 hours of operation 1 and operation 2. In addition, the anastomoc donut or tip of gastric tube is collected during operation 2 (esophagectomy) after formation of the anastomosis.
Induction of angiogenesis by biomarkers of microcirculation
A cytokine profile will be measured in the peripheral blood, consisting of VEGF, IL-8, IL-6, TNF-alpha and Ang-2
Measured: Peripheral blood is taken at the start, or within 24 hours of operation 1
Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography
Redistribution of blood flow by measurement of indocyanine green (ICG)
Measured: During operation 1 and during operation 2 (esophagectomy)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2019
- Study start11 Nov 2019
- Primary completion2 May 2022
- Study completion2 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Esophageal CancerStudies of the same condition, open and under way.
- More trials run by UMC UtrechtThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- UMC Utrecht
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital of Cologne
- Responsible party
- Principal investigator, Richard van Hillegersberg, UMC Utrecht
- Investigators
- Richard van Hillegersberg, MD, PhD, Principal investigator, University Medical Center Utrecht, dept. of SurgeryWolfgang Schröder, MD, PhD, Principal investigator, University Hospital of Cologne, department of Surgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03896399
- Sponsor's protocol ID
- NL67819.041.18
- Acronym
- ISCON
- Status last verified
- May 2022
- First submitted
- 20 Mar 2019
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: This will be published
Publications
Veen AV, Schiffmann LM, de Groot EM, Bartella I, de Jong PA, Borggreve AS, Brosens LAA, Santos DPD, Fuchs H, Ruurda JP, Bruns CJ, van Hillegersberg R, Schroder W. The ISCON-trial protocol: laparoscopic ischemic conditioning prior to esophagectomy in patients with esophageal cancer and arterial calcifications. BMC Cancer. 2022 Feb 5;22(1):144. doi: 10.1186/s12885-022-09231-x.
PubMed 35123419
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Laparoscopic Ischemic Conditioning Prior to Esophagectomy in Patients With Esophageal Cancer and Arterial Calcifications
- ClinicalTrials.gov ID
- NCT03896399
- Acronym / sponsor ID
- ISCON / NL67819.041.18
- Conditions
- Esophageal Cancer
- Keywords
- Esophageal Cancer, Esophagectomy, Ischemic conditioning
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- UMC UtrechtUniversity, hospital or other
- Collaborators
- University Hospital of Cologne
- Study start
- 11 Nov 2019 (actual)
- Primary completion
- 2 May 2022 (actual)
- Study completion
- 2 May 2022 (actual)
- First posted
- 1 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification scores on pre-op CT-scan. In these patients, laparoscopic ischemic conditioning is performed 12-18 days before an Ivor-Lewis esophagectomy. The primary outcome is all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after the laparoscopic ischemic conditioning. Secondary outcomes are complications after the esophagectomy, and the induction of angiogenesis by biomarkers of microcirculation and redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography.
Detailed description
Rationale:
Anastomotic leakage is the most important surgical complication following esophagectomy for esophageal cancer, leading to increased morbidity and mortality. A major cause of leakage is impaired healing due to ischemia of the gastric tube that is used for reconstruction of the gastrointestinal tract. Calcifications of the aorta or stenosis of the celiac trunk on pre-operative CT scan have been shown to be associated with an increased risk of anastomotic leakage. So far, no individualized treatment has been initiated for this selected group of patients. Laparoscopic ischemic conditioning (ISCON) of the gastric tube aims to increase perfusion at the anastomotic site by redistribution of the gastric blood flow and/or induction of angiogenesis. This is achieved by occlusion of the supplying gastric arteries except for the right gastroepiploic artery during a separate intervention prior to esophagectomy. Of note, these arteries would also be occluded during conventional esophagectomy, but with laparoscopic ISCON they are occluded at an earlier moment in time during a separate intervention. Retrospective studies have demonstrated the safety of this technique. Prospective studies have not yet been performed.
Primary objective:
Assess the safety and feasibility of laparoscopic ISCON 12-18 days prior to esophagectomy for esophageal cancer in patients with arterial calcifications.
Study design:
Two center phase II prospective single-arm safety and feasibility trial.
Study population:
Patients with resectable esophageal carcinoma (cT1-4a, N0-3, M0) with "major calcifications" of the thoracic aorta (UCS) and any additional calcification or stenosis of the celiac axis (modified NASCET score) on preoperative CT scan, who are planned to undergo esophagectomy.
Intervention:
Laparoscopic ISCON followed by esophagectomy after an interval of 12-18 days.
Primary outcome:
all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after operation 1 (laparoscopic ISCON) and before operation 2 (esophagectomy).
Secondary outcomes:
secondary outcomes with regard to operation 1 (laparoscopic ISCON) are the duration of the procedure, blood loss, day of discharge postoperatively and grade 1 complications. Secondary outcomes with regard to operation 2 (esophagectomy) are anastomotic leakage rate, all other grade 3b or higher complications and 30 day mortality. Further secondary endpoints are the induction of angiogenesis by biomarkers of microcirculation and redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
the additional burden for the patient consists of an extra operation of approximately 40 minutes during which laparoscopic ISCON will be performed, prior to the planned esophagectomy. We would classify the current study as medium risk. Potential benefits in comparison to current standard treatment are a reduced risk of anastomotic leakage and severity of anastomotic leakage. Potential risks are complications following operation 1 (laparoscopic ISCON). Mainly, based upon prior experience, we expect gastroparesis to occur in 25% of patients. Patients with gastroparesis have an increased risk of aspiration and will require a stomach emptying by nasogastric tube and nasojejunal tube feeding till the performance of operating 2 (esophagectomy).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Laparoscopic ischemic conditioning followed by esophagectomy | Experimental | Procedure: Laparoscopic ischemic conditioning followed by esophagectomyAll included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Histologically proven adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ)
- Planned to undergo transthoracic esophagectomy or transhiatal esophagectomy
- Preoperative computed tomography (CT)
- Vascular arterial changes: "major calcifications" of the thoracic aorta according to the "Uniform calcification score" (UCS) and or a stenosis of the celiac axis according to the "modified NASCET score". (Appendix 1 and 2) (7,17)
- ASA I-III
Key exclusion criteria (2 listed)
- Not able to undergo study treatment.
- Metastatic disease (M1)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Laparoscopic ischemic conditioning followed by esophagectomyAll included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days. | Procedure or surgery | Laparoscopic ischemic conditioning followed by esophagectomy |
Primary outcome
Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning
Time frame: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.
Complications grade 2 and higher (Clavien-Dindo classification)
10 secondary outcomes
Number of participants with a grade 1 complication after operation 1 (laparoscopic ISCON)
Time frame: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.
Duration of operation 1 (laparoscopic ISCON)
Time frame: During operation 1
Bloodloss during operation 1 (laparoscopic ISCON)
Time frame: During operation 1
Day of discharge after operation 1 (laparoscopic ISCON)
Time frame: After operation 1, usually on the third post-operative day
Number of participants with anastomotic leakage after operation 2 (esophagectomy)
Time frame: Within 30 days after operation 2
Number of participants with grade 3b or higher complications after operation 2 (esophagectomy)
Time frame: Within 30 days after operation 2
Number of participants with 30 day mortality after operation 2 (esophagectomy)
Time frame: Within 30 days after operation 2
Induction of angiogenesis in tissue
Time frame: Biopsies are taken at the start, or within 24 hours of operation 1 and operation 2. In addition, the anastomoc donut or tip of gastric tube is collected during operation 2 (esophagectomy) after formation of the anastomosis.
Induction of angiogenesis by biomarkers of microcirculation
Time frame: Peripheral blood is taken at the start, or within 24 hours of operation 1
Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography
Time frame: During operation 1 and during operation 2 (esophagectomy)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Derived from this study: PubMed 35123419Veen AV, Schiffmann LM, de Groot EM, Bartella I, de Jong PA, Borggreve AS, Brosens LAA, Santos DPD, Fuchs H, Ruurda JP, Bruns CJ, van Hillegersberg R, Schroder W. The ISCON-trial protocol: laparoscopic ischemic conditioning prior to esophagectomy in patients with esophageal cancer and arterial calcifications. BMC Cancer. 2022 Feb 5;22(1):144. doi: 10.1186/s12885-022-09231-x.
- Individual participant dataSharing planned: Yes. This will be published
Related trials for Esophageal Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
RecruitingPhase 1
Study of XB010 in Subjects With Solid Tumors
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
RecruitingPhase 2/3
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Mitral Regurgitation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard van Hillegersberg, MD, PhD principal investigator
University Medical Center Utrecht, dept. of Surgery
Wolfgang Schröder, MD, PhD principal investigator
University Hospital of Cologne, department of Surgery
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Laparoscopic ischemic conditioning followed by esophagectomy in people with Esophageal Cancer, run by UMC Utrecht at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning (time frame: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03896399, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.